Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. OnOctober 5, 2021 ,Douglas M. VanOort , the former Chief Executive Officer ofNeoGenomics, Inc. (the "Company") and currently the Company's Executive Chairman and Chairman of the Board of Directors (the "Board") of the Company, notified the Board of his voluntary decision to retire from the Company and that in connection with his retirement he was tendering his resignation as Executive Chairman and Chairman of the Board of the Company, effectiveOctober 7, 2021 .Mr. VanOort will remain as a director on the Board but plans to retire as a member of the Board before the end of the year as the Board concludes an ongoing search process.Mr. VanOort's decision to retire and resign as Executive Chairman and Chairman of the Board was not the result of any dispute or disagreement with the Company, the Company's management or the Board on any matter relating to the operations, policies or practices of the Company. OnOctober 5, 2021 , the Board acknowledgedMr. VanOort's decision to retire, acceptedMr. VanOort's resignation as Executive Chairman and Chairman of the Board of the Company effectiveOctober 7, 2021 , and appointedLynn A. Tetrault , the Company's Lead Independent Director, as the non-executive Chair of the Board, effectiveOctober 7, 2021 .Ms. Tetrault has served as Lead Independent Director of the Board sinceJuly 2020 and has been on the Board sinceJune 2015 . The Board also approvedMs. Tetrault to receive an additional quarterly fee of$15,625 , and an equity grant in the amount of$50,000 for serving as Chair of the Board. Following the effective date of his resignation as Executive Chairman and Chairman of the Board,Mr. VanOort's compensation as a director is consistent with the compensation of other directors as described in the Company's Proxy Statement on Schedule 14A for the Company's 2021 Annual Meeting of Stockholders, which was filed with theSEC onApril 15, 2021 . Item 7.01 Regulation FD Disclosure.
On
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description 99.1 Press Release of NeoGenomics, Inc. dated October 1 2 , 2021. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
© Edgar Online, source